Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections

Seiichi Aonuma, Kotaro Oizumi, Akira Watanabe, Yoshihiro Honda, Yutaka Tokue, Naoto Kitamura, Satoru Shoji, Masakichi Motomiya, Kiyoshi Konno, Kosaku Nagai

    Research output: Contribution to journalArticlepeer-review


    We examined the in vitro antimicrobial activity of cefetamet (CEMT), a metabolite of the orally absorbed cefetamet pivoxil (CEMT-PI), a newly developed cephem antibiotic, by the broth dilution methed using the MIC-2000 system. Minimum inhibitory concentrations (MICs) of CEMT against 120 clinical isolates were compared with those of cefixime (CFIX) and cefaclor (CCL). Against Staphylococcus aureus, CEMT was less active than CFIX and CCL, but against Escherichia coli, Klebsiella pneumoniae and Serratia marcescens it was much more active than CCL, though less active than CFIX. Against Enterobacter cloacae it was as active as CFIX. Eight patients suffering from respiratory tract infections were given 500mg or 1, 000mg of CEMT-PI orally once a day for 3∼8 days. Clinical response was good in seven and fair in one patient Wooziness was observed in one patient.

    Original languageEnglish
    Pages (from-to)106-109
    Number of pages4
    Publication statusPublished - 1990 Jan 1


    • CEMT-PI
    • Cefetamet pivoxil

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Basic and clinical studies on cefetamet pivoxil and its efficacy in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this